Holen Sie sich die Stockscreener-App
76.17
0.92%
-0.775
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt CYTK?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$76.94
Offen:
$77.01
24-Stunden-Volumen:
1.21M
Relative Volume:
0.50
Marktkapitalisierung:
$10.35B
Einnahmen:
$105.82M
Nettoeinkommen (Verlust:
$-829.61M
KGV:
-11.13
EPS:
-6.8429
Netto-Cashflow:
$-548.92M
1W Leistung:
-0.28%
1M Leistung:
+16.71%
6M Leistung:
+11.86%
1J Leistung:
+149.61%
1-Tages-Spanne:
$75.50
$77.26
1-Wochen-Bereich:
$75.50
$79.12
52-Wochen-Spanne:
$29.81
$80.20
Cytokinetics Inc Stock (CYTK) Company Profile
Firmenname
Cytokinetics Inc
Sektor
Branche
Telefon
(650) 624-3000
Adresse
350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Compare CYTK vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CYTK
Cytokinetics Inc
|
76.23 | 10.45B | 105.82M | -829.61M | -548.92M | -6.8429 |
VRTX
Vertex Pharmaceuticals Inc
|
436.69 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.91 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.47 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
294.95 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.71 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cytokinetics Inc Stock (CYTK) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-10 | Eingeleitet | Wells Fargo | Overweight |
| 2026-01-28 | Fortgesetzt | Barclays | Overweight |
| 2025-12-18 | Hochstufung | Goldman | Neutral → Buy |
| 2025-07-30 | Fortgesetzt | Raymond James | Mkt Perform |
| 2025-04-24 | Eingeleitet | Barclays | Overweight |
| 2025-02-07 | Eingeleitet | Citigroup | Buy |
| 2025-01-22 | Eingeleitet | Stifel | Buy |
| 2024-11-08 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-08-13 | Herabstufung | Goldman | Buy → Neutral |
| 2024-01-24 | Herabstufung | UBS | Buy → Neutral |
| 2024-01-05 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2023-11-09 | Eingeleitet | Goldman | Buy |
| 2023-11-07 | Eingeleitet | B. Riley Securities | Buy |
| 2023-08-15 | Eingeleitet | SVB Securities | Outperform |
| 2023-02-17 | Eingeleitet | BofA Securities | Neutral |
| 2022-12-23 | Bestätigt | Needham | Buy |
| 2022-12-20 | Eingeleitet | Truist | Buy |
| 2022-10-11 | Eingeleitet | UBS | Buy |
| 2022-01-28 | Eingeleitet | Goldman | Buy |
| 2021-12-22 | Eingeleitet | Oppenheimer | Outperform |
| 2021-12-10 | Eingeleitet | JP Morgan | Overweight |
| 2021-10-07 | Eingeleitet | Jefferies | Buy |
| 2021-03-12 | Eingeleitet | Wolfe Research | Outperform |
| 2021-02-18 | Eingeleitet | Barclays | Overweight |
| 2021-01-20 | Bestätigt | H.C. Wainwright | Buy |
| 2020-10-29 | Eingeleitet | Goldman | Neutral |
| 2020-07-10 | Eingeleitet | Raymond James | Strong Buy |
| 2020-05-05 | Eingeleitet | Mizuho | Buy |
| 2020-04-09 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2018-09-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-09-10 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2017-11-22 | Bestätigt | Morgan Stanley | Overweight |
| 2017-11-22 | Herabstufung | Needham | Strong Buy → Buy |
| 2017-11-21 | Bestätigt | H.C. Wainwright | Buy |
| 2017-07-31 | Eingeleitet | Morgan Stanley | Overweight |
| 2017-03-08 | Eingeleitet | Rodman & Renshaw | Buy |
| 2017-02-06 | Hochstufung | Needham | Buy → Strong Buy |
| 2016-12-16 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2016-07-28 | Bestätigt | Needham | Buy |
| 2015-11-10 | Bestätigt | FBR Capital | Outperform |
| 2015-11-09 | Bestätigt | ROTH Capital | Buy |
| 2015-07-24 | Bestätigt | MLV & Co | Buy |
| 2014-12-31 | Bestätigt | ROTH Capital | Buy |
| 2014-11-04 | Hochstufung | MLV & Co | Hold → Buy |
| 2014-04-28 | Bestätigt | Needham | Buy |
Alle ansehen
Cytokinetics Inc Aktie (CYTK) Neueste Nachrichten
Cytokinetics says MYKORZO launch tops expectations as HCM data draws praise - MSN
A Look At Cytokinetics (CYTK) Valuation After A Strong Multi‑Year Share Price Performance - Yahoo Finance
Cytokinetics’s SWOT analysis: biotech stock faces profitability test By Investing.com - Investing.com South Africa
Cytokinetics’s SWOT analysis: biotech stock faces profitability test - Investing.com
Cytokinetics Says MYKORZO Launch Tops Expectations as HCM Data Draws Praise - TradingView
Insider Sell Alert: Fady Malik Sells 3,500 Shares of Cytokinetics Inc (CYTK) - GuruFocus
Cytokinetics Insider Sold Shares Worth $264,915, According to a Recent SEC Filing - marketscreener.com
Cytokinetics to Hold Annual Meeting of Stockholders - The Manila Times
Cytokinetics (CYTK) R&D EVP exercises options and sells 3,500 shares - Stock Titan
CYTK: MYQORZO outperforms launch targets, with robust uptake, expanding access, and strong pipeline progress - TradingView
CYTK Initiated Coverage by Citigroup -- Price Target Set at $99. - GuruFocus
Cytokinetics Inc stock (US2328281044): pipeline updates keep biotech in focus - AD HOC NEWS
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - The Manila Times
GABELLI & Co INVESTMENT ADVISERS INC. Sells 23,900 Shares of Cytokinetics, Incorporated $CYTK - MarketBeat
Effect of Aficamten in Women Compared With Men With Obstructive Hypertrophic Cardiomyopathy in SEQUOIA-HCM - American Heart Association Journals
Insider Selling: Cytokinetics (NASDAQ:CYTK) CEO Sells 7,500 Shares of Stock - MarketBeat
Cytokinetics president & CEO Blum sells $584,400 in common stock. By Investing.com - Investing.com Nigeria
Cytokinetics president & CEO Blum sells $584,400 in common stock. - Investing.com
Cytokinetics Inc stock (US2328281044): CLIMB muscle biology symposium adds to MYQORZO launch momentu - AD HOC NEWS
Cytokinetics (CYTK) CEO sells 7,500 shares, holds 400,330 - Stock Titan
Cytokinetics to Host Annual Symposium on Contemporary Landscapes in Muscle Biology (CLIMB) - Yahoo Finance
Q2 EPS Estimates for Cytokinetics Raised by HC Wainwright - MarketBeat
1CYTK.MI Stock Price, Quote & Chart | CYTOKINETICS INC (BIT:1CYTK) - ChartMill
J.P. Morgan Maintains Cytokinetics(CYTK.US) With Buy Rating, Raises Target Price to $97 - Moomoo
CYTK Maintained by JP Morgan -- Price Target Raised to $97.00 - GuruFocus
Cytokinetics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference - The Manila Times
Investors Purchase High Volume of Call Options on Cytokinetics (NASDAQ:CYTK) - MarketBeat
JPMorgan Chase & Co. Issues Positive Forecast for Cytokinetics (NASDAQ:CYTK) Stock Price - MarketBeat
Growth Investors: Industry Analysts Just Upgraded Their Cytokinetics, Incorporated (NASDAQ:CYTK) Revenue Forecasts By 11% - Yahoo Finance
Analysts Are Betting On Cytokinetics, Incorporated (NASDAQ:CYTK) With A Big Upgrade This Week - Moomoo
Cytokinetics (CYTK) Unveils Positive MYQORZO Data at ESC 2026 Co - GuruFocus
One Bay Area company scored $800 million around its heart drug. Here's another targeting the same condition - The Business Journals
CYTK Maintains by HC Wainwright & Co. -- Price Target Raised to $140 - GuruFocus
Cytokinetics completes $805 million public offering - The Pharma Letter
Cytokinetics presents new data on heart drug aficamten - Investing.com
Cytokinetics presents new data on heart drug aficamten By Investing.com - Investing.com South Africa
Cytokinetics Announces New Data Related to MYQORZO® (aficamten) at ESC Heart Failure 2026 - Caledonian Record
Heart drug MYQORZO shows long-term safety as HCM burden detailed - Stock Titan
Cytokinetics, Incorporated (CYTK) Stock Analysis: A Biotech with 35.91% Potential Upside and Groundbreaking Innovations - DirectorsTalk Interviews
Can Myqorzo drive growth for Cytokinetics amid competition? - MSN
Cytokinetics (NASDAQ: CYTK) prices $760.2M common stock sale at $71 - Stock Titan
Cytokinetics closes $805 million stock offering By Investing.com - Investing.com South Africa
Cytokinetics closes $805 million stock offering - Investing.com
Cytokinetics Announces Closing of Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $805 Million - The Manila Times
$805M raised as Cytokinetics sells 11.3M shares at $71 each - Stock Titan
Finanzdaten der Cytokinetics Inc-Aktie (CYTK)
Umsatz
Nettogewinn
Free Cashflow
ENV
Cytokinetics Inc-Aktie (CYTK) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Malik Fady Ibraham | EVP Research & Development |
May 19 '26 |
Sale |
75.69 |
3,500 |
264,915 |
153,902 |
| Blum Robert I | President & CEO |
May 14 '26 |
Sale |
77.92 |
7,500 |
584,400 |
400,330 |
| Malik Fady Ibraham | EVP Research & Development |
May 05 '26 |
Option Exercise |
7.80 |
3,500 |
27,300 |
157,402 |
| Malik Fady Ibraham | EVP Research & Development |
May 05 '26 |
Sale |
77.37 |
3,500 |
270,795 |
153,902 |
2.25%
0.46%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):